Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants
Rhea-AI Filing Summary
Moleculin Biotech, Inc. director, CEO and President Walter V. Klemp reported acquiring 533,333 shares of common stock in a public offering, together with Series I warrants to purchase 1,599,999 shares. The securities were bought at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants. Following these transactions, he directly holds 564,340 common shares and 1,926,335 Series I warrants, which are exercisable for common stock and expire on August 3, 2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 533,333 shares
Net Buy
2 txns
Insider
KLEMP WALTER V
Role
CEO and President
Bought
533,333 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series I Warrants F1 | 1,599,999 | -- | -- |
| Purchase | Common Stock F1 | 533,333 | -- | -- |
Holdings After Transaction:
Series I Warrants — 1,926,335 shares (Direct);
Common Stock — 564,340 shares (Direct)
Footnotes (1)
- F1. On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.
Key Figures
Common shares purchased: 533,333 shares
Total common shares after transaction: 564,340 shares
Series I warrants granted: 1,599,999 warrants
+3 more
6 metrics
Common shares purchased
533,333 shares
Shares of Moleculin Biotech common stock acquired on August 3, 2026 in a public offering
Total common shares after transaction
564,340 shares
Direct holdings of common stock by Walter V. Klemp following the reported purchase
Series I warrants granted
1,599,999 warrants
Series I warrants acquired on August 3, 2026, each exercisable into common stock
Total Series I warrants after transaction
1,926,335 warrants
Direct holdings of Series I warrants by Walter V. Klemp after the grant
Combined purchase price
$0.75
Per one share of common stock and three accompanying Series I warrants in the public offering
Warrant expiration date
August 3, 2031
Expiration date of the reported Series I warrants
Key Terms
Series I Warrants, public offering, combined purchase price, underlying security
4 terms
Series I Warrants financial
"Series I Warrants to purchase 1,599,999 shares of common stock"
public offering financial
"three accompanying warrants in a public offering"
A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.
combined purchase price financial
"at a combined purchase price of $0.75 per one share"
underlying security financial
"underlying_security_title: "Common Stock" as the underlying security"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Moleculin Biotech (MBRX) CEO Walter V. Klemp buy on August 3, 2026?
Walter V. Klemp acquired 533,333 shares of common stock and Series I warrants for 1,599,999 shares of Moleculin Biotech on August 3, 2026, as part of a public offering.
What price did Moleculin Biotech (MBRX) CEO pay in this Form 4 transaction?
The CEO paid a combined purchase price of $0.75 for one share of common stock and three accompanying Series I warrants in the public offering described in the Form 4.
How many Series I warrants does the Moleculin Biotech (MBRX) CEO hold after the grant?
Following the grant, Walter V. Klemp holds 1,926,335 Series I warrants, including 1,599,999 newly acquired warrants, each exercisable for common stock as disclosed in the filing.
When do the Moleculin Biotech (MBRX) Series I warrants held by the CEO expire?
The Series I warrants reported in the Form 4 have an expiration date of August 3, 2031, giving Walter V. Klemp several years to exercise them for common stock.
Was the Moleculin Biotech (MBRX) CEO’s Form 4 transaction part of a public offering?
Yes. The footnote states the CEO acquired 533,333 common shares and 1,599,999 Series I warrants at a combined price of $0.75 per unit in a public offering.